Portfolio
Portfolio

X-Cell Medical

Developing next-generation solutions for restenosis and other cardiovascular clinical applications.

Integrated drug eluting stent (DES) company developing next-generation solutions for restenosis and other cardiovascular clinical applications. X-Cell’s lead program uses 17-ß-estradiol on DES which enhances endothelial growth to help combat sub-acute thrombosis.

Share buy back in 2007.

  • Industry Biotech
  • History Other